Indications
Tecovirimat SIGA is indicated for the treatment of the following viral infections in adults and children with body weight at least 13 kg: Smallpox Monkeypox Cowpox Tecovirimat SIGA is also indicated to treat complications due to replication of vaccinia virus following vaccination against smallpox in adults and children with body weight at least 13 kg (see sections 4.4 and 5.1). Tecovirimat SIGA should be used in accordance with official recommendations.
Composition
- Active substance
- tecovirimat
- International name (INN)
- tecovirimat monohydrate
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Tecovirimat SIGA
- Active substance
- tecovirimat
- ATC code
- J05AX24